https://www.selleckchem.com/pr....oducts/trastuzumab.h
0001), 81% for plasma (79 to 15; P .038), and 75% for platelets (10 to 2.5; P .005). Clinical outcomes improved as well, with composite morbid event rates decreasing by more than 50%, from 236 in 1438 patients (16.4%) to 85 in 1145 patients (7.4%) (P .0001). Mortality and length of stay remained unchanged. Compared to the pre-PBM time period, early-PBM was associated with a risk-adjusted decrease in composite morbidity/mortality (OR 0.73; 95% CI 0.57-0.93; P = .01, while mature-PBM demonstrated a further incremental
Like
Comment
Share
